Skip to main content

Table 2 Correlation between changes in receptor expression and clinical factors

From: The effect of smoking on biological change of recurrent breast cancer

ParametersEstrogen receptorp valueProgesterone receptorp valueHER2p value
Negative conversion (n = 3)The other (n = 47)Negative Conversion (n = 15)No change (n = 35)Positive Conversion (n = 6)No change (n = 44)
Age at operation (years old)
 ≤ 601 (33.3%)25 (53.2%)0.5147 (46.7%)19 (54.3%)0.634 (66.7%)22 (50.0%)0.453
 > 602 (66.7%)22 (46.8%)8 (53.3%)16 (45.7%) 2 (33.3%)22 (50.0%)
Tumor size (mm)
 ≤ 21.81 (33.3%)24 (51.1%)0.56110 (66.7%)15 (42.9%)0.1284 (66.7%)21 (47.7%)0.394
 > 21.82 (66.7%)23 (48.9%)5 (33.3%)20 (57.1%) 2 (33.3%)23 (52.3%)
Lymph node metastasis
 Negative2 (66.7%)41 (87.2%)0.3312 (80.0%)31 (88.6%)0.4346 (100.0%)37 (84.1%)0.302
 Positive1 (33.3%)6 (12.8%)3 (20.0%)4 (11.4%) 0 (0.0%)7 (15.9%)
Ki67 of primary tumor
 ≤ 14%2 (66.7%)17 (36.2%)0.3015 (33.3%)14 (40.0%)0.6641 (16.7%)18 (40.9%)0.26
 > 14%1 (33.3%)30 (63.8%)10 (66.7%)21 (60.0%)5 (83.3%)26 (59.1%)
Chemotherapy after surgery
 No1 (33.3%)36 (76.6%)0.10211 (73.3%)26 (74.3%)0.9455 (83.3%)32 (72.7%)0.588
 Yes2 (66.7%)11 (23.4%)4 (26.7%)9 (25.7%)1 (16.7%)12 (27.3%)
Endocrine therapy after surgery
 No1 (33.3%)13 (27.7%)0.8360 (0.0%)14 (40.0%)0.0032 (33.3%)12 (27.3%)0.762
 Yes2 (66.7%)34 (72.3%)15 (100.0%)21 (60.0%)4 (66.7%)32 (72.7%)
Radiation therapy after surgery
 No1 (33.3%)38 (80.9%)0.05610 (66.7%)29 (82.9%)0.2135 (83.3%)34 (77.3%)0.743
 Yes2 (66.7%)9 (19.1%)5 (33.3%)6 (17.1%)1 (16.7%)10 (22.7%)
Trastuzumab after surgery
 No3 (100.0%)46 (97.9%)0.80415 (100.0%)34 (97.1%)0.5186 (100.0%)43 (97.7%)0.716
 Yes0 (0.0%)1 (2.1%)0 (0.0%)1 (2.9%)0 (0.0%)1 (2.3%)
No-treatment after surgery
 No3 (100.0%)41 (87.2%)0.51915 (100.0%)29 (82.9%)0.0915 (83.3%)39 (88.6%)0.715
 Yes0 (0.0%)6 (12.8%)0 (0.0%)6 (17.1%)1 (16.7%)5 (11.4%)
Age at recurrence (years old)
 ≤ 621 (33.3%)25 (53.2%)0.5148 (53.3%)18 (51.4%)0.9044 (66.7%)22 (50.0%)0.454
 > 622 (66.7%)22 (46.8%)7 (46.7%)17 (48.6%)2 (33.3%)22 (50.0%)
Recurrence site biopsied
 Local, regional lymph node2 (66.7%)43 (91.5%)0.2514 (93.3%)31 (88.6%)0.4586 (100.0%)39 (88.6%)0.715
 Distant metastasis1 (33.3%)4 (8.5%)1 (6.7%)4 (11.4%)0 (0.0%)5 (11.4%)
Change of ER in recurrence
 Negative conversion2 (13.3%)1 (2.9%)0.1590 (0.0%)3 (6.8%)0.519
 The other13 (86.7%)34 (97.1%)6 (100.0%)41 (93.2%)
Change of PgR in recurrence
 Negative conversion2 (66.7%)13 (27.7%)0.1593 (50.0%)12 (27.3%)0.264
 No change1 (33.3%)34 (72.3%)3 (50.0%)32 (72.7%)
Change of HER2 in recurrence
 Positive conversion0 (0.0%)6 (12.8%)0.5193 (20.0%)3 (8.6%)0.264
 No change3 (100.0%)41 (87.2%)12 (80.0%)34 (91.4%)
Disease free survival
 ≤ 7922 (66.7%)23 (48.9%)0.5618 (53.3%)17 (48.6%)0.7643 (50.0%)22 (50.0%)1
 > 7921 (33.3%)24 (51.1%)7 (46.7%)18 (51.4%)3 (50.0%)22 (50.0%)
  1. HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PgR progesterone receptor